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às tomadas de decisão em saúde. Desenvolvimento: A Lógica Paraconsistente é 
uma opção metodológica que permite manipular dados imprecisos, inconsitentes 
e paracompletos. A aplicação do método consiste basicamente de oito etapas: 
1-fixar o nível de exigência da decisão que se pretende tomar; 2-selecionar os 
fatores mais importantes e de maior influência na decisão; 3-estabelecer as seções 
para cada um dos fatores; 4-construir a base de dados que é constituída pelos 
pesos atribuídos aos fatores e pelos valores de evidência favorável e de evidência 
contrária atribuídos a cada um dos fatores em cada uma das seções (os pesos e 
os valores das evidências são atribuídos por especialistas selecionados para o 
estudo); 5-fazer a pesquisa de campo para verificar, no caso em análise, em que 
seção (condição) cada um dos fatores se encontra; 6-obter o valor da evidência 
favorável e o valor da evidência contrária resultantes para cada um dos fatores 
escolhidos, por meio da aplicação das técnicas de maximização e minimização 
da LPAE; 7- obter o grau de evidência favorável e o grau de evidência contrária 
do baricentro dos pontos que representam os fatores escolhidos no reticulado 
paraconsistente; 8-tomar a decisão, aplicando-se a regra de decisão ou algoritmo 
para-analisador. ConClusão: Em situações em que a tomada de decisão precisa 
ser realizada em curto período de tempo, transferir e adaptar avaliações econômi-
cas realizadas em outros contextos pode ser uma necessidade considerável. O 
método paraconsistente pode contribuir nesse processo, apoiando o trabalho das 
comissões hospitalares de avaliação e incorporação de tecnologias em saúde.
DISEASE – SPECIFIC STUDIES
CANCER – Clinical Outcomes Studies
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PhARmACOvIgIlANCE IN ONCOlOgy: KNOwlEDgE AND PERCEPTION ON 
ADvERSE EvENTS REPORTINg IN BRAzIl
Holtz L1, Cecilio L1, Minowa E2, Julian G3
1Oncoguia, São Paulo, Brazil, 2Evidências - Kantar Health, Campinas, Brazil, 3Evidências - Kantar 
Health, São Paulo, Brazil
objeCtives: Pharmacovigilance represents an important tool to support the 
maintenance of drug safety through evaluation of spontaneous adverse events (AE) 
reporting. AEs represent one important cause of morbidity and mortality world-
wide when not managed correctly, being very frequent, especially during oncology 
treatments. However, underreported phenomenon occurs often due inefficient 
spontaneous reporting by patients, physicians and caregivers. Therefore, the aim 
of this survey was to evaluate the knowledge and perception related to pharma-
covigilance in Brazil. methoDs: From February to March 2015, 260 respondents 
answered an internet-based survey related to knowledge on pharmacovigilance 
from Oncoguia Institute, an independent nonprofit cancer advocacy institution. 
Descriptive analyses were performed according to answers frequency. Results: 
Among the respondents, 70.8% were diagnosed with cancer, of which breast cancer 
was the most frequent (58%) followed by colorectal cancer (4%). Reported treat-
ment included chemotherapy (96%), surgery (84%), 48% radiotherapy (48%). Of all, 
46% and 44% were treated by public and private health insurance, respectively. 
Most of the respondents were not aware of the importance of a pharmacovigi-
lance AE report (52%). In fact, 21% of the respondents were not aware of what AEs 
are. In 66% of the cases, physicians have described the main AE expected to the 
prescribed treatment. Respondents reported nausea (80%), hair loss (77%), weight 
gain (49%) and vomiting (45%) as the most common AEs. Only 7% and 4% of the 
respondents were aware that AEs could be reported to pharmaceutical industry 
and ANVISA, respectively. ConClusions: This survey demonstrates that knowl-
edge and perception regarding AEs, such as definition, importance and how to 
proceed in case of having one, including the importance of pharmacovigilance 
system, are very reduced among common public, including cancer patients. 
Therefore, there is an enormous need for educational intervention regarding AEs 
reporting importance in general public, patients and physicians, especially in 
oncology.
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EFICACIA y SEgURIDAD DEl USO DEl CETUxImAB EN PACIENTES CON CANCER 
COlORRECTAl mETASTáSICO
Croci A1, Aleman A2, Perez Galan A2
1Ministry of Public Health, montevideo, Uruguay, 2Ministry of Public Health, Montevideo, Uruguay
objeCtivos: Determinar la eficacia y seguridad de Cetuximab solo o asociado a 
otros fármacos en el tratamiento del cáncer colo-rectal metastásico comparado a los 
tratamientos actualmente disponibles metoDologíAs: Se realizó una búsqueda 
bibliográfica de revisiones sistemáticas y Ensayos Clínicos Aleatorizados (ECAS) en 
bases electrónicas Cochrane, Pubmed y Lilacs, que compararan ramas de tratami-
ento con y sin Cetuximab ResultADos: Se seleccionaron 2 revisiones sistemáti-
cas y 8 ECAS. Los resultados para los puntos finales de eficacia y seguridad en la 
población general fueron: Sobrevida Global (SG) HR 0,97 [0,89-1,05], Sobrevida Libre 
de Progresión (SLP) HR 0,84 [0,70-0,98], eventos adversos (EA) grado 3-4 HR 2,15 [1,88-
2,45] y reacciones de piel 44,5 [22,1-89,5]. En la población KRAS wild la SG fue HR 
0,796 IC95% [0,670-0,946] en el estudio de Van Cutsem, HR, 0,855 IC95% [0,599-1,219] 
en el estudio de Bokemeyer, 1,04 IC95% [0,87-1,23] en el estudio de Maughan y HR 
0,55 IC95% [0,41-0,74] en el estudio de Jonker. Para la SLP en población KRAS wild 
los resultados fueron HR 0,57 IC95% [0,38-0,86] en el estudio de Bokemeyer, HR 0,40 
IC95% [0,30-0,53] en el estudio de Jonker, HR 0,96 IC96% [0,82-1,12] en el estudio de 
Maughan y HR 0,70 IC95% [0,56-0,87] en el estudio de Van Cutsem ConClusiones: 
Los resultados analizados muestran un incremento en la SG en pacientes con KRAS 
wild y de la SLP. También se constata un incremento en la ocurrencia de EA graves. 
Considerando los resultados de eficacia y seguridad para Cetuximab, se recomienda 
realizar un estudio de costo-efectividad para decidir su posible inclusión en el FTM. 
En este sentido, no debe darse por concluida la evaluación hasta contar con dicha 
información.
bonded to SV by hydrophobic interactions, while OH groups are oriented towards 
the outer side of the aggregate. Hence, the formed aggregate is more hydrophilic 
than SV molecule alone. ConClusions: Our data indicate that CA decreases the 
values of SV distribution coefficient. This may be the result of the formation of 
hydrophilic complexes increasing the solubility of SV that could consequently lead 
to the increase of SV bioavailability. In order to confirm these results, further in 
vivo investigations of their interactions at molecular level need to be undertaken. 
Acknowledgement: This work is supported by Ministry of Education, Science and 
Technological Development of Serbia, Project III41012.
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COmPARISON OF ChRONIC hEPATITIS C TREATmENT EFFICACy IN 
RANDOmIzED CONTROllED TRIAlS AND REAl-lIFE STUDIES - INFlUENCE OF 
STUDy DESIgN IN ThE SUSTAINED vIROlOgICAl RESPONSE: A SySTEmATIC 
REvIEw OF PUBlIShED lITERATURE
Vaisberg VV, Kim V, Ono SK, Mendes LC, Carrilho FJ
University of São Paulo School of Medicine, São Paulo, Brazil
objeCtives: To assess whether hepatitis C treatment outcome was similar among 
different study designs. methoDs: Two independent reviewers conducted a 
double-screened systematic review on hepatitis C treatment. Studies were cat-
egorized under study design: randomized controled trials (RCT), pragmatic trials 
(PRG) and registries; and treatment course: pegylated interferon and ribavirin (IR), 
IR and boceprevir (BCP), IR and telaprevir (TLP). 3,713 abstracts were retrieved, 
and 253 studies were included according to previously selected criteria, compris-
ing 77,042 patients. Sustained virological response (SVR) was stablished as treat-
ment end-point. Mann-Whitney-U and Kruskall-Wallis tests were used with a 95% 
CI. Results: In the IR group, registries had a lower SVR than PRG (P= 0.039) and than 
RCT (P= 0,3368). RCT had a worse outcome than PRG (P= 0.283). Statistical difference 
was seen among the three BCP groups (P= 0.040), and RCT had a higher SVR than 
registries (P= 0.028). BCP PRG group couldn’t be analysed in comparison to other 
study designs due to a very small group. PRG (SVR= 80.13%) had a better outcome 
than RCT (SVR= 75.00%) and than registries (SVR= 62.00%), but tests have shown 
no statistical significance among study designs (P> 0.05). ConClusions: It’s pos-
sible to design close to the real-life settings RCT. Though it’s not a rule, each drug 
should be studied separately and its clinical scenario considered. PRG might be not 
as pragmatic as they claim to be, as their results were more similar to RCT than to 
registries. Further analysis should assess whether PRG are fully bridging RCT’s gap to 
the real-life settings, as they are intent to be the main guide to drug’s embodiment to 
the clinical practice. Also, boceprevir was less studied than telaprevir, and whether 
remains unclear which drug is more effective, new data could answer that, specially 
a large proportions head-to-head RCT comparing both drugs. Although, as of new 
and better treatment courses are approved, this RCT most probably will not be done.
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ENgAgINg hISPANIC CAREgIvERS IN RESEARCh: A FRAmEwORK TO DESIgN 
CUlTURAlly SENSITIvE APPROAChES FOR ENgAgEmENT IN  
PATIENT-CENTERED OUTCOmES RESEARCh
Camelo Castillo W1, Hendricks J2, dosReis S3
1University of Maryland School of Pharmacy School of Pharmacy, Baltimore, MD, USA, 2Maryland 
Coalition fo Families for Children’s Mental Health, Hagerstown, MD, USA, 3University of Maryland 
School of Pharmacy, Baltimore, MD, USA
The Latin American perspective on caregivers’ preferences is underrepresented in 
research largely due to lack of culturally sensitive approaches to enhance research 
literacy. Identification of the most effective engagement strategies is needed so 
that patient centered outcomes research (PCOR) can address the needs and pri-
orities of caregivers of Latin American origin. Our objectives were to develop a 
methodological framework for engaging caregivers of Latin American origin in 
research and to improve PCOR literacy in this population. The ‘pre-engagement’ 
framework with hard-to-reach patients was used in a study designed to identify 
caregivers’ priorities for treatment and outcomes in children of Hispanic origin 
living in the U.S. with complex mental health conditions. Based on the principles 
of community based participatory research, the pre-engagement implementa-
tion phases were: 1. Identify Hispanic community leaders with common goals; 2. 
Partner with leaders to select key topics of interest; 3. Design culturally appropriate 
strategies; 4. Implement pre-engagement strategies. During phase 1, academic 
partnerships were developed with community leaders to allow integration into the 
research process. Community needs and practical challenges to engage caregivers 
and the strategies to overcome barriers were identified during phase 2. In phase 
3, a series of four workshops, delivered in Spanish, were designed as interac-
tive activities each addressing a unique challenge: understanding the caregiver’s 
perspective, understanding the child’s perspective, providing behavior manage-
ment strategies, and discussing community resources for families. Each workshop 
emphasized research literacy by linking the benefit of research in advancing the 
challenge being discussed. An outcome of this work will be a caregiver resource 
guide in Spanish, developed by Hispanic community leaders, for distribution in 
their communities. In the absence of culturally appropriate tools to address health 
and medical preferences of non-English speaking communities, this framework 
can be used to engage caregivers and communities in patient-centered research.
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O méTODO PARACONSISTENTE COmO SUPORTE ÀS TOmADAS DE DECISãO Em 
SAúDE
Campolina AG, Costa A, López RV
Cancer Institute of the State of São Paulo, Sao Paulo, Brazil
intRoDução: O presente estudo objetiva apresentar a Lógica Paraconsistente 
Anotada Evidencial (LPAE), que é a base teórica para o modelo proposto de suporte 
